TWiV 1154: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin discusses the Marburg virus outbreak in Rwanda, the lack of immune durability following pertussis vaccination, recommendations for maternal vaccination and antibody therapy to protect against infant RSV, vaccine security for Mpox, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how to put on and take off PPE to avoid contamination, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, the lack of immune durability elicited by mRNA vaccine and the finding of how SARS-CoV-2 infection impacts memory, cognition and reduces grey matter volume.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Rwanda: Marburg virus disease (WHO)
• Passport required?…..Marburg virus commutes to Germany (CIDRAP)
• Outbreak of whooping cough/pertussis…..no lifelong immunity following vaccination? (Bloomberg
• Protection of infants by maternal antibodies against RSV by either vaccination or nirsevimab (MMWR)
• WHO recommendations for RSV: maternal vaccination and antibody shot (Reuters)
• Ziresovir for RSV hospitalized infants (NEJM)
• Crawling to effective anti-RSV countermeasures (NEJM)
• The $800 million pledge for African mpox response (Reuters)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Doffing your PPE– contact precautions (CID)
• mRNA vaccination does not elicit durable immune response (Nature Medicine)
• IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Mechanisms of long COVID and therapeutics (Cell)
• Post hospitalization cognitive deficits and grey matter reduction 1 year after COVID-19 (Nature Medicine)
• Letters read on TWiV 1154
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]